Difference between revisions of "Pfizer"
m (added sourcewatch & powerbase) |
(→COVID-19 vaccine: adding insider selloffs) |
||
| Line 22: | Line 22: | ||
==COVID-19 vaccine== | ==COVID-19 vaccine== | ||
On 9 November 2020, Pfizer and partner [[BioNTech]] announced that their vaccine against [[COVID-19]] was strongly effective, exceeding expectations with results that are likely to be met with cautious excitement — and relief — in the face of the global pandemic. | On 9 November 2020, Pfizer and partner [[BioNTech]] announced that their vaccine against [[COVID-19]] was strongly effective, exceeding expectations with results that are likely to be met with cautious excitement — and relief — in the face of the global pandemic. | ||
| + | |||
| + | Pfizer CEO [[Albert Bourla]] instantly cashed in on the announcement, selling 60 percent of his Pfizer stock at $41.99, its highest level in more than a year. <ref>http://d18rn0p25nwr6d.cloudfront.net/CIK-0000078003/57afef57-8280-4e7f-9b8c-78bb14852af9.pdf</ref> The sale had been arranged in advance under a so-called Rule 10b5-1 trading plan, which allows corporate executives to make predetermined stock transactions in compliance with [[insider trading laws]]. Bourla adopted the trading plan in August of this year.<ref>https://www.anti-empire.com/pfizer-ceo-sold-62-of-his-stock-on-day-of-vaccine-reveal/</ref> | ||
| + | |||
| + | Also [[Sally Susman]], the company’s executive vice president and chief corporate affairs officer, dumped more than 43,000 shares to the tune of about $1.8 million. <ref>http://d18rn0p25nwr6d.cloudfront.net/CIK-0000078003/b3aabe38-af36-4936-a888-627803d27cd9.pdf</ref> The sale was similarly made under a Rule 10b5-1 plan Susman adopted in November 2019. | ||
The vaccine is the first to be tested in the [[United States]] to generate late-stage data. The companies said an early analysis of the results showed that individuals who received two injections of the vaccine three weeks apart experienced more than 90% fewer cases of symptomatic [[Covid-19]] than those who received a placebo. For months, researchers have cautioned that a vaccine that might only be 60% or 70% effective. | The vaccine is the first to be tested in the [[United States]] to generate late-stage data. The companies said an early analysis of the results showed that individuals who received two injections of the vaccine three weeks apart experienced more than 90% fewer cases of symptomatic [[Covid-19]] than those who received a placebo. For months, researchers have cautioned that a vaccine that might only be 60% or 70% effective. | ||
| Line 29: | Line 33: | ||
In keeping with guidance from the [[Food and Drug Administration]], the companies will not file for an emergency use authorisation to distribute the vaccine until they reach another milestone: when half of the patients in their study have been observed for any safety issues for at least two months following their second dose. Pfizer expects to cross that threshold in the third week of November: | In keeping with guidance from the [[Food and Drug Administration]], the companies will not file for an emergency use authorisation to distribute the vaccine until they reach another milestone: when half of the patients in their study have been observed for any safety issues for at least two months following their second dose. Pfizer expects to cross that threshold in the third week of November: | ||
:“I’ve been in vaccine development for 35 years,” said [[William Gruber]], Pfizer’s senior vice president of vaccine clinical research and development. “I’ve seen some really good things. This is extraordinary.” He later added: “This really bodes well for us being able to get a handle on the epidemic and get us out of this situation.”<ref>''[https://www.statnews.com/2020/11/09/covid-19-vaccine-from-pfizer-and-biontech-is-strongly-effective-early-data-from-large-trial-indicate/ "Covid-19 vaccine from Pfizer and BioNTech is strongly effective, early data from large trial indicate"]''</ref> | :“I’ve been in vaccine development for 35 years,” said [[William Gruber]], Pfizer’s senior vice president of vaccine clinical research and development. “I’ve seen some really good things. This is extraordinary.” He later added: “This really bodes well for us being able to get a handle on the epidemic and get us out of this situation.”<ref>''[https://www.statnews.com/2020/11/09/covid-19-vaccine-from-pfizer-and-biontech-is-strongly-effective-early-data-from-large-trial-indicate/ "Covid-19 vaccine from Pfizer and BioNTech is strongly effective, early data from large trial indicate"]''</ref> | ||
| + | |||
| + | |||
| + | |||
| + | |||
| + | |||
| + | |||
| + | |||
{{SMWDocs}} | {{SMWDocs}} | ||
| + | |||
==References== | ==References== | ||
{{reflist}} | {{reflist}} | ||
Revision as of 13:23, 12 November 2020
 Pfizer  (Big pharma)     | |
|---|---|
 | |
| Formation | 1849 |
| Interest of | Ehden Biber, Tiffany Dover, Fazze, Owen Smith, Cristian Terheș, Vasudha Vats |
| Member of | Alliance for Biosecurity, Business Roundtable, Council on Foreign Relations/Corporate Members, Transatlantic Policy Network |
| Sponsored by | Bill & Melinda Gates Foundation |
| Exposed by | Michèle Rivasi |
| Subpage | •Pfizer/CEO •Pfizer/Vice President |
Pfizer Inc. is a multinational pharmaceutical corporation headquartered in New York City. In 2012, it was one of the world's largest pharmaceutical companies and ranked 57 on the 2018 Fortune 500 list of the largest United States corporations by total revenue.[1][2]
Contents
Products
Pfizer develops and produces medicines and vaccines for a wide range of medical disciplines, including immunology, oncology, cardiology, endocrinology, and neurology. Its products include the blockbuster drug Lipitor (atorvastatin), used to lower Low-density lipoprotein (LDL) blood cholesterol; Lyrica (pregabalin) for neuropathic pain and fibromyalgia; Diflucan (fluconazole), an oral antifungal medication; Zithromax (azithromycin), an antibiotic; Viagra (sildenafil) for erectile dysfunction; and Celebrex (also Celebra, celecoxib), an anti-inflammatory drug.
Mergers
In 2016, Pfizer was expected to merge with Allergan to create the Ireland-based "Pfizer plc" in a deal that would have been worth US$160 billion.[3] The merger was called off in April 2016, however, because of new rules from the US Department of the Treasury against tax inversions, a method of avoiding taxes by merging with a foreign company.[4] The company has made the second-largest pharmaceutical settlement with the United States Department of Justice.
On 19 December 2018, Pfizer announced a joint merger of their consumer healthcare division with UK pharma giant GlaxoSmithKline which maintains a controlling 68% of shares.[5]
COVID-19 vaccine
On 9 November 2020, Pfizer and partner BioNTech announced that their vaccine against COVID-19 was strongly effective, exceeding expectations with results that are likely to be met with cautious excitement — and relief — in the face of the global pandemic.
Pfizer CEO Albert Bourla instantly cashed in on the announcement, selling 60 percent of his Pfizer stock at $41.99, its highest level in more than a year. [6] The sale had been arranged in advance under a so-called Rule 10b5-1 trading plan, which allows corporate executives to make predetermined stock transactions in compliance with insider trading laws. Bourla adopted the trading plan in August of this year.[7]
Also Sally Susman, the company’s executive vice president and chief corporate affairs officer, dumped more than 43,000 shares to the tune of about $1.8 million. [8] The sale was similarly made under a Rule 10b5-1 plan Susman adopted in November 2019.
The vaccine is the first to be tested in the United States to generate late-stage data. The companies said an early analysis of the results showed that individuals who received two injections of the vaccine three weeks apart experienced more than 90% fewer cases of symptomatic Covid-19 than those who received a placebo. For months, researchers have cautioned that a vaccine that might only be 60% or 70% effective.
The Phase 3 study is ongoing and additional data could affect results.
In keeping with guidance from the Food and Drug Administration, the companies will not file for an emergency use authorisation to distribute the vaccine until they reach another milestone: when half of the patients in their study have been observed for any safety issues for at least two months following their second dose. Pfizer expects to cross that threshold in the third week of November:
- “I’ve been in vaccine development for 35 years,” said William Gruber, Pfizer’s senior vice president of vaccine clinical research and development. “I’ve seen some really good things. This is extraordinary.” He later added: “This really bodes well for us being able to get a handle on the epidemic and get us out of this situation.”[9]
An event carried out
| Event | Location | Description |
|---|---|---|
| Foster child drug trials | New York US | In the nightmarish, surreal world of pediatric clinical trials, infants, toddlers, children and teenagers in New York and around the United States are forced to ingest dangerous, toxic pharmaceuticals, arranged by the National Institutes of Health and Big Pharma. |
Related Quotations
| Page | Quote | Author | Date |
|---|---|---|---|
| COVID-19/Resistance | “I have done my bit and been vaccinated because we were told that was the route to protect others and regain our freedoms. Neither was correct. I will not allow my perfectly healthy body to become a cash cow for Pfizer.” | Allison Pearson | 9 December 2021 |
| Dominic Cummings | “In March [2020] I started getting calls from various people saying these new mRNA vaccines could well smash the conventional wisdom. [. . .] People like Bill Gates and that kind of network were saying. [. . .] Essentially what happened is, [. . .] there is a network of people, Bill Gates type people, who were saying completely rethink the paradigm of how you do this.. What Bill Gates and people like that were saying to me and others in number 10 was you need to think of this much more like the classic programs of the past. [. . .] the Manhattan Project in WWII, the Apollo program.. But what Bill Gates and people were saying [. . .] was, the actual expected return on this is so high that even if does turn out to be all wasted billions it's still a good gamble [. . .] and that is what we did.” | Dominic Cummings | May 2021 |
Employees on Wikispooks
| Employee | Job | Appointed | End | Description |
|---|---|---|---|---|
| Hans Groth | Senior Director for Healthcare Policy & Market Access | 1988 | 2012 | Attended 2011 Bilderberg. |
| Owen Smith | Head of Policy and Government Relations | 2005 | 2010 |
Sponsor
| Event | Description |
|---|---|
| Bill & Melinda Gates Foundation | Very influential and rich foundation established to take leadership of global health. |
Related Document
| Title | Type | Publication date | Author(s) | Description |
|---|---|---|---|---|
| Document:Researcher blows the whistle on data integrity issues in Pfizer’s vaccine trial | article | 2 November 2021 | Paul D Thacker | Whistleblowers from a contract research company helping to carry out Pfizer’s pivotal covid-19 vaccine trial say never experienced such a “helter skelter" work environment, saying speed may have come at the cost of data integrity and patient safety. |
References
- ↑ "Pfizer moves higher amid persistent breakup talk"
- ↑ "Fortune 500 Companies 2018: Who Made the List"
- ↑ "Pfizer to buy Allergan in $160 billion deal"
- ↑ "Pfizer, Allergan scrap $160 billion deal after U.S. tax rule change"
- ↑ "GlaxoSmithKline and Pfizer merge healthcare arms"
- ↑ http://d18rn0p25nwr6d.cloudfront.net/CIK-0000078003/57afef57-8280-4e7f-9b8c-78bb14852af9.pdf
- ↑ https://www.anti-empire.com/pfizer-ceo-sold-62-of-his-stock-on-day-of-vaccine-reveal/
- ↑ http://d18rn0p25nwr6d.cloudfront.net/CIK-0000078003/b3aabe38-af36-4936-a888-627803d27cd9.pdf
- ↑ "Covid-19 vaccine from Pfizer and BioNTech is strongly effective, early data from large trial indicate"
